Paul Chaplin, a member of the executive management team at Bavarian Nordic A/S is taking over as president and chief executive officer, replacing Anders Hedegaard who has led the company since 2007. Mr Hedegaard is leaving Bavarian Nordic to join GN ReSound A/S, a producer of hearing aid technology.
Dr Chaplin has been head of research at Bavarian Nordic and led the development programme for the company’s smallpox vaccine. Since 2010 he has been division president, infectious diseases. Under his leadership, Bavarian Nordic received its first product approval in 2013.
Dr Chaplin holds a PhD in immunology from Bristol University in the UK.
Bavarian Nordic announced the appointment on 28 May 2014.
Copyright 2014 Evernow Publishing Ltd